Back to Results
First PageMeta Content
Epigenetics / Hepatology / Hepatocellular carcinoma / Sorafenib / Hep G2 / DNA methylation / Methylation / Liver cancer / Hypomethylating agent / Biology / Chemistry / Genetics


SGI-110, a novel second generation DNA hypomethylating agent, enhances sorafenib activity and alters the methylation signature of HCC cell lines No[removed]Simone Jueliger1, John Lyons1, Mohammad Azab2 and Pietro Taverna2
Add to Reading List

Open Document

File Size: 456,76 KB

Share Result on Facebook

City

Dublin / Cambridge / /

Company

Qiagen / GelCount Counting System Oxford Optronix Ltd. / Astex Pharmaceuticals Inc. / Pietro Taverna2 Astex Pharmaceuticals / /

Country

United Kingdom / United States / Ireland / /

Event

FDA Phase / /

IndustryTerm

Cancer Therapeutics / /

MedicalCondition

tumor / ovarian cancer / tumors / scid / hepatocellular carcinoma / carcinogenesis / tumour / /

Person

Crystal Violet / /

Product

1way ANOVA / SGI-110 / /

ProvinceOrState

California / /

URL

www.astx.com / /

SocialTag